You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 133 No. 2, February 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (28)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Otolaryngology/ Head & Neck Surgery
 •Endocrine Surgery
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Outcome of Subtotal Parathyroidectomy for the Treatment of Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1

John R. Burgess, MB, BS, FRACP; Rueben David; Venkateswaran Parameswaran, PhD; Tim M. Greenaway, PhD, FRACP; Joseph J. Shepherd, FRACS

Arch Surg. 1998;133:126-129.

Background  The efficacy of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1 (MEN 1) is unclear. The long-term outcome and optimal timing of operation remain controversial.

Objective  To determine the long-term outcome of parathyroidectomy for primary hyperparathyroidism in the presence of MEN 1.

Design  Case series and retrospective analysis.

Setting  Tertiary referral center.

Patients  Patients with MEN 1 from 2 families.

Interventions  Subtotal parathyroidectomy, ie, resection of 3 parathyroid glands from each patient.

Main Outcome Measures  Recurrence of hyperparathyroidism.

Results  Thirty-seven patients underwent subtotal parathyroidectomy. Overall, persistent postoperative hypoparathyroidism developed in 24%, normocalcemia was maintained in 46%, and hyperparathyroidism recurred in 30%. However, after adjustment for the duration of follow-up (by using the Kaplan-Meier method), the cumulative recurrence rates for hyperparathyroidism were 15% at 2 years, 23% at 4 years, 55% at 8 years, and 67% after 8 years. Early recurrence of hyperparathyroidism (within 5 years of operation) was less likely to develop in patients in whom ionized calcium levels of 1.00 mmol/L (4.00 mg/dL) or less were achieved during the perioperative period than in patients in whom this degree of hypocalcemia failed to develop (P=.01).

Conclusions  While relatively long periods of disease remission are possible after subtotal parathyroidectomy, our results indicate that recurrent hyperparathyroidism eventually develops in most patients with MEN 1.


From the Departments of Diabetes and Endocrine Services (Drs Burgess, Parameswaran, and Greenaway) and Clinical Chemistry (Mr David), Royal Hobart Hospital, Hobart, and the Department of Surgery (Dr Shepherd), University of Tasmania, Tasmania, Australia.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Percutaneous Parathyroid Ethanol Ablation in Patients with Multiple Endocrine Neoplasia Type 1
Veldman et al.
Am. J. Roentgenol. 2008;191:1740-1744.
ABSTRACT | FULL TEXT  

Subtotal parathyroidectomy as an adequate treatment for primary hyperparathyroidism in multiple endocrine neoplasia type 1.
Hubbard et al.
Arch Surg 2006;141:235-239.
ABSTRACT | FULL TEXT  

Osteoporosis in Multiple Endocrine Neoplasia Type 1: Severity, Clinical Significance, Relationship to Primary Hyperparathyroidism, and Response to Parathyroidectomy
Burgess et al.
Arch Surg 1999;134:1119-1123.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.